Literature DB >> 2095340

Package inserts for antihypertensive drugs: use by the patients and impact on adverse drug reactions.

C H Van Haecht1, R Vander Stichele, M G Bogaert.   

Abstract

In Belgium, all dispensed drugs are provided with package inserts. Traditional physician-orientated inserts are gradually being replaced by patient package inserts (PPIs). The present survey is focused on the use of inserts for antihypertensive drugs and their impact on the reported occurrence and attribution of adverse drug reactions (ADRs). A group of 28 general practitioners (GPs) from the Flemish part of Belgium collected data from 702 hypertensive patients. Each participating GP submitted a consecutive sample of his patients to an interview in the Spring 1989, when 25% of the antihypertensive specialties carried a PPI-version. 1049 prescriptions for antihypertensive drugs had been dispensed. Two thirds of the patients, mostly those with a higher educational level, had read the package inserts. PPIs accounted for 16% of the inserts, and they had not been read significantly more than the traditional inserts. Reporting by the patients of possible drug-related health problems (spontaneously + after having heard the items on a check-list) was not affected by reading the insert or by the type of insert. However, the PPI did bring about spontaneous reporting, especially by patients with a low educational level. Attribution of at least one health problem to the medication was not affected by reading in itself but by the type of insert. Attribution was higher when the patient had received a PPI, except in the case of highly educated patients. Spontaneous reporting and attribution of health problems to the medications prescribed was found more frequently among patients with higher education, who did not seem to need a PPI to recognize problems as being drug-related.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095340     DOI: 10.1007/bf00316093

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  A symptom questionnaire for hypertensive patients.

Authors:  C J Bulpitt; C T Dollery; S Carne
Journal:  J Chronic Dis       Date:  1974-08

2.  The patient package insert. Is it safe and effective?

Authors:  R Dorsey
Journal:  JAMA       Date:  1977-10-31       Impact factor: 56.272

3.  Dr. Tice on patient package inserts.

Authors:  L F Tice
Journal:  Am Pharm       Date:  1978-01

4.  The benefits of prescription information leaflets (1).

Authors:  S Gibbs; W E Waters; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

5.  Patient medication instruction and provider interactions: effects on knowledge and attitudes.

Authors:  P L De Tullio; S A Eraker; C Jepson; M H Becker; E Fujimoto; C L Diaz; R B Loveland; V J Strecher
Journal:  Health Educ Q       Date:  1986

6.  Informing patients about drug side effects.

Authors:  L A Morris; D E Kanouse
Journal:  J Behav Med       Date:  1982-09
  6 in total
  4 in total

Review 1.  Written information about individual medicines for consumers.

Authors:  Donald Nicolson; Peter Knapp; D K Theo Raynor; Pat Spoor
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

2.  Conformity of package inserts information to regulatory requirements among selected branded and generic medicinal products circulating on the East African market.

Authors:  Hiiti B Sillo; Nelson E Masota; Sunday Kisoma; Lembit Rago; Veronica Mgoyela; Eliangiringa A Kaale
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

Review 3.  Eliciting adverse effects data from participants in clinical trials.

Authors:  Elizabeth N Allen; Clare Ir Chandler; Nyaradzo Mandimika; Cordelia Leisegang; Karen Barnes
Journal:  Cochrane Database Syst Rev       Date:  2018-01-16

4.  An investigation on patient attitudes toward package inserts and their accessibility in Iran.

Authors:  Parisa Ahmadi; Shirin S Badri; Amir H Zargarzadeh
Journal:  J Res Med Sci       Date:  2018-11-28       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.